On Wednesday, BofA Securities increased the price target for Vaxcyte (NASDAQ:PCVX) to $140 from the previous $101, while maintaining a Buy rating on the stock. This adjustment follows Vaxcyte's announcement of encouraging Phase 1/2 trial results for VAX-31, a pneumococcal vaccine tested in adults.
The positive momentum for Vaxcyte shares, which have seen a 35% rise, is attributed to the vaccine's immunogenicity results in adults over 50. The mid and high doses of VAX-31 met the statistical non-inferiority criteria for all 20 serotypes that it shares with the active study comparator, Pfizer’s Prevnar-20, and also achieved the statistical criteria set for novel serotypes.
According to the firm, these outcomes are viewed as an optimal de-risking event for VAX-31, suggesting a potential to lead the market for pneumococcal conjugate vaccines (PCVs), valued at over $8 billion. Vaxcyte plans to progress VAX-31 into Phase 3 trials for the adult indication by mid-2025 and intends to sequentially develop its 24-valent and 31-valent PCVs for infants.
The firm's analyst cited that the current data reduces the risk for the broader VAX-31 program, especially when adult data can be indicative of results in infants. Consequently, the probability of success for the program has been increased to 70% from the previous 60%, and the nominal peak market share projection has been raised to $6 billion from $5 billion.
The firm reiterates its Buy rating on PCVX, highlighting the company's potential to further unlock the value of its PCV program. The detailed model updates reflecting these changes have been outlined in Exhibit 1 of the firm's report.
In other recent news, Vaxcyte has been making significant strides in the development of its pneumococcal conjugate vaccine candidate, VAX-31. Following promising results from a Phase 1/2 trial, the vaccine has been given a Buy rating by TD Cowen, BTIG, and Jefferies. The vaccine aims to provide broader protection against invasive pneumococcal disease compared to current market leaders, covering over 95% of circulating strains in the United States and 98% in the European Union.
Vaxcyte has also announced a public offering of $1.0 billion in common stock and pre-funded warrants, with the offering managed by several financial institutions, including BofA Securities, Jefferies, Leerink Partners, and Goldman Sachs (NYSE:GS) & Co. LLC. This coincides with the company's ongoing efforts to develop vaccines against bacterial diseases.
In addition to these developments, Vaxcyte has appointed John P. Furey to its Board of Directors, indicating recent changes in the company's corporate structure. The company plans to advance VAX-31 to a Phase 3 program for adult immunization by mid-2025.
InvestingPro Insights
Following BofA Securities' price target increase for Vaxcyte, real-time data and InvestingPro Tips provide a deeper dive into the company's financial health and stock performance. Vaxcyte's market capitalization stands at a robust $12.29 billion, indicating significant investor confidence and market valuation. Despite the company's promising clinical trial results, it's important to note that Vaxcyte's Price/Earnings (P/E) Ratio is currently negative at -24.32, reflecting that the company is not generating profits at this time.
InvestingPro Tips highlight that Vaxcyte holds more cash than debt on its balance sheet, which is a positive sign for the company's financial stability. However, analysts have expressed concerns by revising their earnings downwards for the upcoming period, which investors should consider. Additionally, the stock is suggested to be in overbought territory according to the Relative Strength Index (RSI), which may indicate a potential pullback in the share price.
Despite these concerns, Vaxcyte has experienced significant returns over the past week, month, and year, with a one-week price total return of 40.44% and a one-year price total return of 107.44%. The strong recent performance may reflect market optimism following the trial results and the upgraded price target. For readers interested in a more comprehensive analysis, InvestingPro offers additional tips on Vaxcyte at https://www.investing.com/pro/PCVX, providing valuable insights for potential investors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.